AstraZeneca has sold the rights in the U.S. for infant lung infection treatment Synagis to Swedish Orphan Biovitrum for $1.5 billion.
The deal gives Sobi a much larger U.S. footprint and expand its business in immunology. Nearly 130 AstraZeneca staff will transfer to Sobi, which will begin marketing of Synagis in the U.S.
AstraZeneca will receive $1 billion in cash and $500 million in Sobi shares. Including deferred and contingency payments, the deal's total value may reach $2.3 billion.
Read the Reuters report